Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas.

Am J Clin Pathol. 2012 Dec;138(6):837-44.

Hirschmann A, Lamb TA, Marchal G, Padilla M, Diebold J.

Institute of Pathology, Lucerne Cantonal Hospital, Lucerne, Switzerland.

 

Abstract

This study sought to evaluate a new combined gene and protein detection platform in the context of HER2 evaluation in breast and gastric carcinomas. HER2 immunohistochemistry (IHC) and dual color in situ hybridization (Dual ISH) were combined on a single slide. Results were compared with conventional HER2 IHC and fluorescence ISH. Results from the gene and protein assay were reliable and highly reproducible for both breast and gastric carcinomas. Concordance was found between conventional HER2 IHC and ISH testing and the gene and protein assay in the same laboratory (>95% for Dual ISH; lower for IHC because of different antibody clones), between IHC and Dual ISH performed on the same slide (>92%), and in the gene and protein assays between laboratories (>96%). This cost- and time-effective method provides fast and definitive results (IHC confirmed by means of Dual ISH) to aid in rapid treatment decisions. It can also be applied to other gene and protein combinations.

PMID: 23161718

 

Additional Information

Ventana Medical Systems, Inc.’s (Ventana) HybClear Solution enables the detection of a primary antibody using VENTANA IHC detection kits in combination with the detection of a DNP labeled entity using VENTANA ISH DNP detection technology and/or a DIG labeled entity using VENTANA ISH DIG detection technology on a single section of formalin-fixed, paraffin-embedded human tissue on a VENTANA BenchMark Series (BenchMark GX, BenchMark XT, and BenchMark ULTRA) slide staining instrument.

The Gene and Protein Platform also stains paraffin-embedded cell pellets and xenograft slides.

The Gene and Protein Platform allows for the use of user-fillable antibodies and probes for further customer optimization.

Whereas most customers are using the Gene Protein Platform to detect HER2 in breast and gastric tissue, many applications are possible; for example, the detection of EGFR, IGF1R, and cMET in lung cancer.

 

Picture references:

 

 

Picture 1: HER2 Low Expressing in Breast Tissue

 

 

Picture 2: HER2 Moderately Expressed in Breast Tissue

 

 

Picture 3: HER2 Highly Expressed in Breast Tissue

 

 

Picture 4: EGFR Expressed in Lung Tissue

 

 

Picture 5: IGF1R Expressed in Xenograft Slide

 

 

Picture 6: cMET Expressed in Lung Cell Pellets

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann